SGLT2 Inhibition in Heart Failure: New Updates

Published: 08 February 2023

  • Views:

    Views Icon 10510

  • Likes:

    Heart Icon 7
  • episode_image
    12m 35s
    Part 10 Panel Discussion
    Harriette Van Spall, Nandini Gupta, Scott Solomon, Muthiah Vaduganathan, Orly Vardeny, Eileen O’Meara
  • episode_image
    15m 19s
    Part 5 Panel Discussion Harriette Van Spall, Nandini Gupta, Subodh Verma, John JV McMurray, Xiaowen “Wendy” Wang, Pardeep Jhund
Average (ratings)
No ratings
Your rating

Overview

This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.

 

Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.

 

Note, the live version of this session was CME accredited; this on-demand version is not.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
  • To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
  • To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
  • To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
  • To assess the merit of ejection fraction in heart failure care

Target Audience

  • Primary Care Physicians
  • Endocrinologists
  • Nephrologists
  • Cardiologists
  • Nurses
  • Pharmacists
  • Dietitians
  • Diabetes Educators

More from this programme

Part 1

Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?

1 session
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors? Watch now

Part 2

SGLT2 Inhibition in the Elderly and Frail Patients

1 session
SGLT2 Inhibition in the Elderly and Frail Patients Watch now

Part 3

Gender Differences in Outcomes With SGLT2 Inhibitors

1 session
Gender Differences in Outcomes With SGLT2 Inhibitors Watch now

Part 4

Efficacy and Safety of SGLT2 Inhibitors in Black Patients

1 session
Efficacy and Safety of SGLT2 Inhibitors in Black Patients Watch now

Part 5

Panel Discussion

1 session
Panel Discussion Watch now

Part 6

SGLT2 Inhibition in Patients With Improved EF

1 session
SGLT2 Inhibition in Patients With Improved EF Watch now

Part 7

SGLT2 Inhibition With MRAs and ARNis

1 session
SGLT2 Inhibition With MRAs and ARNis Watch now

Part 8

Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?

1 session
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors? Watch now

Part 9

Does EF Still Matter in HF Management?

1 session
Does EF Still Matter in HF Management? Watch now

Part 10

Panel Discussion

1 session
Panel Discussion Watch now

Faculty Biographies

Orly Vardeny

Orly Vardeny

Associate Professor of Medicine

Dr Orly Vardeny is Associate Professor of Medicine at the University of Minnesota in Minneapolis. Her research interests include maximising the benefit of pharmacologic therapy in patients with heart failure and optimising vaccination strategies in patients with cardiac disorders. She has led several multi-center, randomized clinical trials evaluating influenza vaccines in patients with high-risk cardiovascular disease.

In addition, Dr Vardeny serves as the US national lead investigator and a steering committee member for numerous clinical trials investigating novel therapies in patients with heart failure. Her clinical practice is in the outpatient management of patients with chronic heart failure. She is an Associate Editor for Circulation: Heart Failure and was a writing group member for the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guidelines for the Management of Heart Failure.

View full profile